Our mission is to digitalize biology: transform biology into numbers and numbers into biology.
Comprehensive it infrastructure
For medical research
Aardens accelerates medical advances with applying the latest technological breakthroughs.
Dynamic legal consent
Smartcontract-based dynamic legal consent - ethical patient enrollment methods.
Machine learning
Machine learning technologies for medical screening and diagnostics systems
Epidemic surveillance
Epidemic surveillance combined with biological teleportation
Our mission is to digitalize biology: transform biology into numbers and numbers into biology.
For investors
Second source of income
Aardens uses its idle money for long term value investments. The company invests into large size US and European companies using methods developed by Benjamin Graham and Warren Buffett adapted to today's conditions.
The aim is to create a secondary source of income, and at the same time lower the traditionally high risk and volatility of the biotechnology business model in a transparent way.
Investment opportunity
Aardens is privately owned.
If you are a traditional investor and have questions, please do not hesitate to contact us.
Micro investment
In 2023 Aardens will launch a micro-investment opportunity for private investors.
We will publish the details on our website soon.
If you are interested, send us your contact information and we will get back to you as soon as the details are available.
About the company
Aardens is a genomics intelligence company focusing on technology intensive genomics research and development in relation to medicine.
The company develops systems for
clinical data collection, coupled with smart contract based, dynamic legal consent methods,
systems for infection control and surveillance
scalable, automated systems for genomic material collection from research participants,
AI based medical screening methods, and
genomics data sharing technologies,
machine learning based diagnostics methods.
Leaning on the new data protection regulation of European Union (GDPR), Aardens has developed a cutting-edge dynamic patient consent method using smartcontract technology. We believe that our technology may become industry standard in the near future not just in Europe but also in North America.
GenTree
Aardens’ flagship project is GenTree Community Biobank.
Aardens provides GenTree with complete technology infrastructure, such as data management and storage system, smartcontract-based dynamic patient consent, and cryptographic solutions.
Aardens is also responsible for organizing DNA sample-, and data collection campaigns, financial and administrative management.
Aardens’ further role is to be an intermediary organization between GenTree and pharma and biotechnology companies.
Contact us
Please fill the form below with your questions and we will get back in no time.
Company
Aardens Biosciences OÜ
Address
Ahtri tn 12, Tallinn, 10151
2022. All rights reserved.